GMAB News and Press, Genmab A/S From 10/27/22

Summary Legend Biotech's Carvykti was approved this year for the treatment of fourth and fifth-line-plus multiple myeloma. Carvykti is partnered with J&J, and the launch is off to a strong start despite supply challenges, thanks to the outstanding CARTITUDE-1 trial data. L...

Genmab ( GMAB ) has announced Q3 worldwide net trade sales of $2.05B for Darzalex (daratumumab) anti-cancer monoclonal antibody medication, compared with $1.99B generated in Q2 . Net trade sales were USD 1.09B in the U.S. and USD 955M in the rest of the world. Genmab (...

Summary Investors are flocking to USD, and most foreign currencies are now weak. On the surface, investment implications seem slight, but it is quite the contrary. This article will highlight the current market implications and ways that a strong USD influences foreign assets....

Summary As it successfully transitioned into a commercial-stage operator, Seagen is enjoying great progress. The four drugs powering Seagen's marketed portfolio are generating robust revenue growth. Meanwhile, various catalysts like the recent LAVA deal would deliver much long...

Summary Beijing YishengBio will merge with a SPAC vehicle, Summit Healthcare Acquisition, to list on the Nasdaq Exchange at a pre-money equity value of $834 million. Simcere Pharma of Nanjing announced a $507 million out-licensing to Spain’s Almirall for ex-China rights to ...

-- Zai Lab Obtains Exclusive Rights to Develop and Commercialize TIVDAK, an FDA-approved First-in-Class Antibody-Drug Conjugate (ADC), in Mainland China, Hong Kong, Macau, and Taiwan -- -- Zai Lab will Leverage its Leadership in Women’s Cancer in China to Commercialize and ...

Pharmaceutical/biotechnology is the subsector with the highest value and quality scores. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. 10 stocks cheaper than their peers in August. This monthly article series shows a dashboa...

Image source: The Motley Fool. Genmab A/S (NASDAQ: GMAB) Q2 2022 Earnings Call Aug 10, 2022 , 12:00 p.m. ET Operator Continue reading For further details see: Genmab A/S (GMAB) Q2 2022 Earnings Call Transcript

Genmab A/S (GMAB) Q2 2022 Results Conference Call August 10, 2022 12:00 PM ET Company Participants Jan van de Winkel - President and CEO Anthony Pagano - CFO Judith Klimovsky - Chief Development Officer Anthony Mancini - COO Tahi Ahmadi - Chief Medical Of...

Genmab A/S press release ( GMAB ): Q2 GAAP EPS of DKK28.66. Revenue of DKK3.16B (+60.4% Y/Y). Shares +1.4% . On Aug. 08, the company raised its FY22 guidance . For further details see: Genmab A/S GAAP EPS of DKK28.66, revenue of DKK3.16B